Page 43 - ITPS-7-4

INNOSC Theranostics and
Pharmacological Sciences Pediatric drug regulations in India

patients with asthma. Respir Med. 2006;100(8):1307-1317. doi: 10.1177/2168479016646809
doi: 10.1016/j.rmed.2005.11.020 45. Rei Bolislis W, Bejeuhr G, Benzaghou F, et al. Optimizing
pediatric medicine developments in the European Union
34. Anyanwu LJC, Mohammad AM. Gastrointestinal bleeding
following NSAID ingestion in children. Ann Pediatr Surg. through pragmatic approaches. Clin Pharmacol Ther.
2013;9(2):87-89. 2021;110(4):871-879.
doi: 10.1097/01.XPS.0000428237.26252.84 doi: 10.1002/cpt.2152
35. Kim KH, Kim DS. Juvenile idiopathic arthritis: Diagnosis and 46. De Rojas T, Kearns P, Blanc P, et al. Changing incentives
differential diagnosis. Korean J Pediatr. 2010;53(11):931-935. to ACCELERATE drug development for paediatric cancer.
Cancer Med. 2023;12(7):8825-8837.
doi: 10.3345/kjp.2010.53.11.931
doi: 10.1002/cam4.5627
36. Nițescu V, Lescaie A, Boghițoiu D, Ulmeanu C.
Benzalkonium chloride poisoning in pediatric patients: 47. Kreeftmeijer-Vegter AR, de Boer A, van der Vlugt-Meijer RH,
Report of case with a severe clinical course and literature de Vries PJ. The influence of the European paediatric
review. Toxics. 2024;12(2):139. regulation on marketing authorisation of orphan drugs for
children. Orphanet J Rare Dis. 2014;9(1):120.
doi: 10.3390/toxics12020139
doi: 10.1186/s13023-014-0120-x
37. Shahramian I, Ostad Rahimi P, Radvar S. Hyperosmolar
hyperglycemic state in children: Case report and review of 48. Thomsen MDT. Global pediatric drug development. Curr
the literature. J Clin Endocrinol Metab. 2022;15(2):60-62. Ther Res Clin Exp. 2019;90:135-142.
doi: 10.1007/s41969-022-00164-1 doi: 10.1016/j.curtheres.2019.02.001
38. Terms of Reference of the Steering UNICEF/WHO: Sources 49. Government of India. Training Modules (1-4) for Programme
and Prices of Selected Medicines for Children Reflection Paper Managers & Medical Officers National TB Elimination
on Ethical and GCP Aspects of Clinical Trials of Medicinal Programme Central TB Division. New Delhi: Central TB
Products for Human Use Conducted in Third Countries and Division Ministry of Health and Family Welfare, National
Submitted in Marketing Authorization Applications to the TB Elimination Programme Central TB Division Ministry
EMA; 2010. Available from: https://www.ema.europa.eu of Health & Family Welfare, Government of India; 2020.
[Last accessed on 2024 Apr 24]. p. 1-201. Available from: https://tbcindia.gov.in/index1.
php?lang=1&level=1&sublinkid=5465&lid=3540 [Last
39. Christensen ML. Best pharmaceuticals for children act and accessed on 2024 Apr 28].
pediatric research equity act: Time for permanent status.
J Pediatr Pharmacol Ther. 2012;17(2):140-141. 50. Sampson MR, Benjamin DK, Cohen-Wolkowiez M.
Evidence-based guidelines for pediatric clinical trials:
doi: 10.5863/1551-6776-17.2.140 Focus on StaR Child Health. Expert Rev Clin Pharmacol.
40. Li H, Shi FH, Huang SY, Zhang SG, Chen HW. The best 2012;5(5):525-531.
pharmaceuticals for children-what can we do? Transl doi: 10.1586/ecp.12.52.
Pediatr. 2020;9(2):86-92.
51. Fiebig D. Preparing the paediatric investigation plan
doi: 10.21037/TP.2020.02.07 application. Med Writ. 2012;21(2):108-113.
41. Bourgeois FT, Hwang TJ. The pediatric research equity act doi: 10.1179/2047480612z.00000000022
moves into adolescence. JAMA. 2017;317(3):259-260.
52. Tomasi P. Writing applications for paediatric investigation
doi: 10.1001/jama.2016.18131 plans and waivers. Med Writ. 2012;21(2):104-107.
42. Chinmayi CS, Pratheksha S, Mude L, Parvathaneni M, doi: 10.1179/2047480612z.00000000021
Kalaivanan R, Karri VVS. An overview and comparison of
regulatory pathways and guidelines for pediatric study plans 53. Wang Y, Chen D, He J. A brief introduction to China’s new
in the US and EU. J Med Chem Sci. 2023;6(12):3057-3071. drug administration law and its impact on medications for
rare diseases. Intractable Rare Dis Res. 2019;8(4):226-230.
doi: 10.26655/JMCHEMSCI.2023.12.21
doi: 10.5582/irdr.2019.01133
43. Milne CP. Paediatric assessment: An essential part of standard
drug development. Int J Pharm Med. 2006;20(5):297-301. 54. Wu WW, Ji X, Mou XS, et al. Trends in innovative
pediatric drug development in China based on clinical trial
doi: 10.2165/00124363-200620050-00003
registration data. Front Med (Lausanne). 2023;10:1187547.
44. Egger GF, Wharton GT, Malli S, Temeck J, Murphy MD,
Tomasi P. A comparative review of waivers granted in doi: 10.3389/fmed.2023.1187547
pediatric drug development by FDA and EMA From 55. Meng M, Liu E, Zhang B, et al. Guideline for the management
2007-2013. Ther Innov Regul Sci. 2016;50(5):639-647. of pediatric off-label use of drugs in China (2021). BMC

Volume 7 Issue 4 (2024) 18 doi: 10.36922/itps.3831